Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study
Authors:
- 16 May 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 8 (4) , 297-302
Abstract
Metronidazole is traditionally dosed every 6–8 hours even though in adults it has a long half-life, concentration-dependent killing, and 3-hour postantibiotic effect. Based on this logic, some pediatric hospitals adopted once-daily dosing for appendicitis, despite limited pharmacokinetics-pharmacodynamics (PK/PD) in children. We studied pediatric patients with appendicitis given metronidazole once daily to determine whether this dosing would meet target area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio of ≥70 for Bacteroides fragilis. One hundred pediatric patients aged 4–17 years had an average of 3 blood draws per patient during the first 24 hours after a 30 mg/kg per dose of intravenous metronidazole. Concentrations of drug were determined using validated liquid chromatography and tandem mass spectrometry. A NONMEM model was constructed for determining PK, followed by Monte Carlo simulations to generate a population of plasma concentration-time AUC of metronidazole and hydroxy-metronidazole. Simulated AUC values met target attainment (AUC/MIC ratio of ≥70 to B fragilis MICs) for 96%–100% of all patients for an MIC of 2 mcg/mL. For MICs of 4 and 8 mcg/mL, target attainment ranged from 61% to 97% and 9% to 71%, respectively. Areas under the curve were similar to that of adults receiving 1000 mg and 1500 mg q24, or 500 mg q8 hours. Metronidazole, 30 mg/kg per dose, once daily achieved AUC target attainment for B fragilis with an MIC of 2 mcg/mL or less in pediatric appendicitis patients. Based on this and studies in adults, there does not seem to be any PK/PD advantage of more frequent dosing in this population.Keywords
This publication has 24 references indexed in Scilit:
- Therapeutic Equivalence Requires Pharmaceutical, Pharmacokinetic, and Pharmacodynamic Identities: True Bioequivalence of a Generic Product of Intravenous MetronidazoleAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Metronidazole Evaluated Using Scavenged Samples from Preterm InfantsAntimicrobial Agents and Chemotherapy, 2012
- Initial laparoscopic appendectomy versus initial nonoperative management and interval appendectomy for perforated appendicitis with abscess: a prospective, randomized trialJournal of Pediatric Surgery, 2010
- An evidence-based definition for perforated appendicitis derived from a prospective randomized trialJournal of Pediatric Surgery, 2008
- Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trialJournal of Pediatric Surgery, 2008
- Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failureBritish Journal of Clinical Pharmacology, 2007
- Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazoleDiagnostic Microbiology and Infectious Disease, 2006
- Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas , and Peptostreptococcus SpeciesAntimicrobial Agents and Chemotherapy, 2001
- Pharmacokinetics and Pharmacodynamics of the Nitroimidazole AntimicrobialsClinical Pharmacokinetics, 1999
- MetronidazoleDrugs, 1997